MedPath

A study to compare combination regimen with vildagliptin & metformin versus metformin in treatment-naive patients with type 2 diabetes mellitus

Phase 1
Conditions
Type 2 Diabetes Mellitus
Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
Registration Number
EUCTR2011-003712-23-EE
Lead Sponsor
ovartis Pharma Services AG
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
Not specified
Target Recruitment
2000
Inclusion Criteria

- T2DM diagnosed =24 months ago
- HbA1c = 6.5% and =7.5% at visit 1
- Treatment-naive
- Body mass index (BMI) = 22 AND=40 kg/M2 at Visit 1

Other protocol-defined inclusion criteria may apply
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

- Pregnant or nursing (lactating) women
- Previous or currrent participation in any vildagliptin clinical study
- History of hypersensitivity to DPP-4 inhibitors
- Concurrent medical condition that may interfere with the interpretation of efficacy and safety data during the study
- Donation of blood or significant blood loss equaling to at least one unit of blood within the past 2 weeks of start of study or a blood transfusion within the past 12 weeeks or planned regular transfusions during the sutdy period

Other protocol-defined exclusion criteria may apply

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath